Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Risk of colorectal high-grade dysplasia and cancer in IBD

A prospective study in the latest issue of Gastroenterology investigates the risk of colorectal high-grade dysplasia and cancer in patients with IBD.

News image

There is an unclear risk of colonic high-grade dysplasia and colorectal cancer among patients with inflammatory bowel disease treated with immunosuppressants.

Dr Laurent Beaugerie and colleagues analyzed data on colorectal cancer development among patients with inflamatory bowel disease enrolled in the observational cohort Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France.

The research team followed and collected data from 19,486 patients with inflamatory bowel disease enrolled in Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France from 2004 to 2005, and followed them until 2007.

When the study began, 2841 patients were characterized as having long-standing extensive colitis.

Early lesions high-grade dysplasia and colorectal cancer were defined as those diagnosed within 10 years after diagnosis of inflammatory bowel disease.

The standardized incidence ratios of colorectal cancer were 2.2 for all IBD patients
Gastroenterology

The researchers evaluated 37 patients that developed colorectal cancer during the follow-up period, and 20 developed colorectal higher-grade dysplasia.

The standardized incidence ratios of colorectal cancer were 2.2 for all inflammatory bowel disease patients, 7.0 for patients with long-standing extensive colitis, and 1.1 for patients without long-standing extensive colitis.

Among patients with long-standing extensive colitis, the multivariate adjusted hazard ratio for colorectal high-grade dysplasia and cancer was 0.28 for those who received thiopurines compared with those who never received thiopurine therapy.

The team observed that 22 patients developed early lesions.

The research team noted that 7 of these were related to inflammatory bowel disease, based on histologic analysis.

Dr Beaugerie's team comments, "Patients with IBD and long-standing extensive colitis are at increased risk for colorectal cancer, although the risk is lower among patients receiving thiopurine therapy."

"Patients without long-standing extensive colitis have a risk for colorectal cancer similar to that of the general population, but they can develop inflammatory bowel disease-related lesions within 10 years after diagnosis of inflamatory bowel disease."

Gastroenterol 2013: 145(1): 166-175
18 July 2013

Go to top of page Email this page Email this page to a colleague

 31 March 2015

Advanced search
 31 March 2015 
Hepatic fat and gallbladder polyps
 31 March 2015 
HCV-HIV co-infection combination therapy
 31 March 2015 
Placement of nasoenteral feeding tubes
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry
 30 March 2015 
Treatment of pediatric IBD
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease
 27 March 2015 
Sexual functioning in IBD
 26 March 2015 
Survival of untreated hepatocellular carcinoma
 26 March 2015 
Antimicrobial therapy in cirrhosis with spontaneous bacterial peritonitis
 26 March 2015 
Metformin as a chemopreventive agent for Barrett's
 25 March 2015 
Genetics and Crohn's disease
 25 March 2015 
Mortality in Barrett’s–related T1 esophageal adenocarcinoma
 25 March 2015 
Cytomegalovirus and IBD
 24 March 2015 
Prevention of colorectal cancer after screening
 24 March 2015 
Functional GI disorders and body mass index
 24 March 2015 
Quality of life in children with fecal incontinence
 23 March 2015 
Fibrosis in NAFLD vs NASH
 23 March 2015 
The unmasking of Whipple's disease
 23 March 2015 
Predicting the quality of colon cancer care
 20 March 2015 
Screening for Barrett's esophagus
 20 March 2015 
Interventions for eosinophilic esophagitis
 20 March 2015 
Colorectal cancer risk and genetic variants
 19 March 2015 
Dedicated care for diverticular disease
 19 March 2015 
Hypnotherapy for IBS
 19 March 2015 
Poor mental and physical health in HCV
 18 March 2015 
Practice guidelines for colorectal polyps
 18 March 2015 
Out-of-hours endoscopy for upper GI bleeding
 18 March 2015 
H. pylori eradication and lipids
 17 March 2015 
H. pylori test-and-treat program and gastric cancer
 17 March 2015 
Adalimumab in Crohn’s disease
 17 March 2015 

Low-dose PPIs and GI bleeding in patients receiving aspirin

 16 March 2015 
Cholestasis of pregnancy with HCV
 16 March 2015 
Microscopic colitis
 16 March 2015 
Hybrid therapy for H. pylori
 13 March 2015 
Medicare patients and payments to gastroenterologists
 13 March 2015 
Appendectomy in ulcerative colitis
 13 March 2015 

Racial disparities in gluten-sensitive problems

 12 March 2015 
Predicting IBD in IBS patients
 12 March 2015 
Patient knowledge of IBS
 12 March 2015 
Nonceliac gluten sensitivity
 11 March 2015 

Prediction of malignant bile duct obstruction

 11 March 2015 
NAFLD–related hepatocellular carcinoma
 11 March 2015 
Assessment of eosinophilic esophagitis
 10 March 2015 
Risk for gastroesophageal reflux symptoms
 10 March 2015 
Poor disease course in pediatric ulcerative colitis
 10 March 2015 
Outcomes in Crohn's therapy
 09 March 2015 
Fibre usage in ulcerative colitis in remission
 09 March 2015 
Risk of C. difficile upon hospital admission
 09 March 2015 
Gastric Cancer detection during GI endosocopy
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 04 March 2015 
Progression of Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us